Every 10-Q that Coherus Oncology, Inc. (CHRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CHRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHRS filings page.
Coherus Oncology, Inc. reported Q2 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier, driven mainly by LOQTORZI sales of $13.6 million. Gross margin from continuing operations was 70%.
Research and development expense fell to $21.4 million and selling, general and administrative expense to $21.0 million, reflecting lower headcount and the exit from biosimilars. The company recorded a Q2 2026 net loss from continuing operations of $33.3 million and total net loss of $20.6 million, partly offset by $12.7 million of income from discontinued operations tied to prior biosimilar divestitures.
At June 30, 2026, Coherus held $105.3 million in cash, cash equivalents and marketable securities, with a $37.2 million 2029 term loan and a $14.8 million revenue participation liability outstanding. Management believes existing liquidity funds operations for at least 12 months but indicates additional capital will be needed to complete development and commercialization plans.
Coherus Oncology reported first-quarter 2026 net revenue of $12.3 million, up from $7.6 million a year earlier, driven mainly by LOQTORZI sales of $11.8 million. Gross margin from continuing operations improved to 69%, reflecting higher oncology volume.
The company still posted a net loss of $38.3 million versus $56.6 million in 2025, with continuing operations accounting for a $36.9 million loss. Coherus strengthened liquidity through a February 2026 equity offering, raising $53.6 million net and ending the quarter with $167.0 million in cash, cash equivalents and marketable securities.
Coherus Oncology (CHRS) reported Q3 2025 results. Continuing operations net revenue was $11,571, driven by LOQTORZI revenue of $11,169. Loss from continuing operations was $(44,517). Discontinued operations contributed net income of $8,986, resulting in a quarterly net loss of $(35,531).
The company closed the divestiture of the UDENYCA franchise on April 11, 2025 for upfront cash of $483.4 million, recognizing a net gain of $338.7 million. Proceeds were used to redeem substantially all 2026 convertible notes and to buy out UDENYCA royalty rights for $47.7 million.
As of September 30, 2025, cash and cash equivalents were $103,352 and investments in marketable securities were $88,311. Total assets were $516,519, total liabilities $428,745, and stockholders’ equity was $87,774. Shares outstanding were 116,236,018 at quarter end.